• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network

    5/21/26 7:30:00 AM ET
    $OPRX
    Real Estate
    Real Estate
    Get the next $OPRX alert in real time by email

    WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent, the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx's proprietary electronic health record (EHR) network into its healthcare advertising platform.

    By combining OptimizeRx's authenticated EHR network with DeepIntent's healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP workflows, using the same programmatic tools they already rely on for digital media buying. This collaboration also reflects the growing demand for privacy-safe advertising solutions tied to real clinical workflows.

    "Our integration with DeepIntent makes validated EHR inventory easier to activate within a platform our clients already trust and value," said Steve Silvestro, Chief Executive Officer at OptimizeRx. "As we expand programmatic access to our authenticated EHR network, our focus is helping more brands deliver measurable point of care engagement."

    Bringing Programmatic Buying into the Clinical Workflow

    As healthcare marketers navigate growing signal loss, tighter privacy standards, and other limitations across traditional open-web advertising, demand is growing for more deterministic, measurable ways to reach providers at clinically relevant moments.

    Building on DeepIntent's existing point of care and omnichannel capabilities, the OptimizeRx integration enables life science marketers to:

    • Access OptimizeRx's authenticated EHR inventory directly within DeepIntent's platform
    • Extend omnichannel campaigns into point of care environments
    • Reach providers closer to clinical decision moments
    • Activate scalable point of care campaigns with the speed, control, and flexibility of programmatic buying

    DeepIntent is widely recognized for its healthcare-focused DSP capabilities, including audience targeting, activation, optimization, and measurement solutions designed specifically for life sciences brands. Adding reach within OptimizeRx's proprietary EHR network helps marketers better align media activation with provider engagement across the care journey.

    "We're excited to bring OptimizeRx's industry-leading EHR network to our established client base of pharmaceutical brands, healthcare agencies, and enterprise marketers," said Lisa Kopp Johnson, Chief Revenue Officer, DeepIntent. "By offering scalable access to providers directly within their clinical workflows, we can help deliver more timely and relevant information that supports informed care decisions and better patient outcomes. This partnership comes as DeepIntent is building the richest marketplace of vital inventory relevant to our clients."

    Expanding Access to Point of Care Media

    The DeepIntent collaboration reflects OptimizeRx's broader strategy to expand programmatic access to its authenticated EHR network through select DSP partnerships. By opening its infrastructure to additional demand-side integrations over time, the company aims to make clinically aligned point of care media more accessible within modern healthcare advertising workflows.

    Availability

    OptimizeRx's authenticated EHR network is expected to be available on the DeepIntent platform in Q3 2026. For more information about availability or to inquire about DSP integration opportunities, please contact us at https://www.optimizerx.com/contact-us.

    About OptimizeRx

    OptimizeRx is a leading healthcare technology company that's redefining how life sciences brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. 

    Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all. 

    For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.

    About DeepIntent

    DeepIntent is the leading healthcare demand-side platform (DSP), purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. Trusted by the world's top healthcare brands and their agencies, DeepIntent uniquely unites media, identity, and real-world clinical data to power privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent's platform delivers measurable audience quality and script lift at scale. Learn more at www.deepintent.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will", "can", "activate", "access", "expanding", "incorporate", "connecting" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the availability of OptimizeRx's EHR inventory on the DeepIntent DSP, the growing demand for privacy-safe advertising solutions tied to real clinical workflows, the success of pharmaceutical brands to deliver measurable point of care management, the ability of healthcare marketers to activate point of care campaigns at scale, expansion of programmatic access to the Company's EHR network, and the accessibility of clinically aligned point of care media within healthcare advertising workflows. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

    OptimizeRx Contact

    Jennifer Dinkel, VP Marketing 

    jdinkel@optimizerx.com

    OptimizeRx Investor Relations Contact

    Douglas Farrell 

    LifeSci Advisors, LLC 

    dfarrell@lifesciadvisors.com

    OptimizeRx Press Inquiries

    Matter Communications

    optimizerx@matternow.com 

    DeepIntent Press Inquiries

    Press@deepintent.com

    OptimizeRx Partnership Inquiries

    Louis Trivento, SVP Strategic Partnerships 

    ltrivento@optimizerx.com 



    Primary Logo

    Get the next $OPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    SEC Filings

    View All

    SEC Form DEFA14A filed by OptimizeRx Corporation

    DEFA14A - OptimizeRx Corp (0001448431) (Filer)

    6/1/26 7:30:04 AM ET
    $OPRX
    Real Estate

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    5/13/26 4:04:37 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    5/12/26 4:07:01 PM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    B. Riley Securities resumed coverage on OptimizeRx with a new price target

    B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

    7/25/24 8:24:56 AM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Greco Theresa covered exercise/tax liability with 1,793 shares, decreasing direct ownership by 2% to 71,075 units (SEC Form 4) (withholding obligation)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    5/18/26 4:44:34 PM ET
    $OPRX
    Real Estate

    Chief Executive Officer Silvestro Stephen L covered exercise/tax liability with 5,219 shares, decreasing direct ownership by 3% to 185,288 units (SEC Form 4) to satisfy withholding tax

    4 - OptimizeRx Corp (0001448431) (Issuer)

    5/18/26 4:43:36 PM ET
    $OPRX
    Real Estate

    SEC Form 3 filed by new insider Presti Mariyamma Varghese

    3 - OptimizeRx Corp (0001448431) (Issuer)

    4/22/26 10:57:29 AM ET
    $OPRX
    Real Estate

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OptimizeRx to Participate in Upcoming Investor Conferences

    WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference, Boston, June 2 – 3, 202646th Annual William Blair Growth Stock Conference, Chicago, June 2 – 4, 2026 Stifel 2026 Boston Cross Sector 1x1 ConferenceDate:  Tuesday, June 2, 2026 Format: 1x1 Meetings Location: InterContinental Boston   William Blair & Company's 46th Annual Growth Stock ConferenceDate:  Wednesday, June

    6/1/26 7:30:00 AM ET
    $OPRX
    Real Estate

    DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network

    WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent, the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx's proprietary electronic health record (EHR) network into its healthcare advertising platform. By combining OptimizeRx's authenticated EHR network with DeepIntent's healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP wor

    5/21/26 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

    – Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "

    5/12/26 4:01:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report

    WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2026. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. ESG Report Highlights The appointment of Mary Varghese Presti to our Board of Directors as an independent director furthers our ongoing process to refresh

    4/29/26 4:05:00 PM ET
    $OPRX
    Real Estate

    Myomo Appoints William J Febbo to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William "Will" Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Febbo is an accomplished executive, entrepreneur, and investor with over 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations and acquisitions, and significant ca

    4/16/26 4:05:00 PM ET
    $MYO
    $OPRX
    Industrial Specialties
    Health Care
    Real Estate

    OptimizeRx Appoints Mary Varghese Presti to Board of Directors

    WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent director is in furtherance of the Company's ongoing process to refresh and expand its Board of Directors. Varghese Presti brings more than 25 years of experience at the intersection of healthcare, life sciences, and technology, with a track record of building and scaling platforms that translate innovation into real-world

    4/8/26 4:05:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

    – Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "

    5/12/26 4:01:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET

    WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2026. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date: Tuesday, May 12, 2026 Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) Toll Free: 1-

    4/28/26 8:00:00 AM ET
    $OPRX
    Real Estate

    UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

    3/5/26 5:04:30 PM ET
    $OPRX
    Real Estate

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate